Nicotine therapy method and oral carrier for assuaging tobacco-addiction

ABSTRACT

A method for assuaging tobacco addiction comprises pulsing doses of nicotine into a user&#39;s bloodstream so it reaches the brain before passing through the liver. A nicotine-burst tablet is held in the mouth by a user to receive each nicotine-pulse dose. The tablet is configured to suddenly release its entire nicotine payload from an otherwise inert or benign material. Such nicotine payload is relatively small, e.g., under one milligram. The therapeutic effects depend on the change of nicotine levels in the blood over a change in time. Rapid nicotine onset of a small dose is more assuaging than a slow build-up to a high dosage. An oral carrier comprises a nicotine saturated instant-dissolve paper that delivers one nicotine pulse. An additive prevents abuse by causing excessive use to catalyze a foul taste or sickening sensation.

RELATED APPLICATIONS

[0001] This Application is a continuation-in-part of U.S. patentapplication Ser. No. 09/771,454, filed Jan. 29, 2001, and which is, inturn, a continuation-in-part of U.S. patent application Ser. No.09/292,045, filed Apr. 14, 2001, and now issued as U.S. Pat. No.6,248,760, on Jun. 19, 2001. Such are incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates to tobacco-addiction therapies, andmore particularly to methods and devices for assuaging nicotine cravingsin users.

[0004] 2. Description of Related Art

[0005] Tobacco-addiction is a serious health problem through out theworld. The hundreds of compounds carried along with the nicotine causemost of the trouble, but the nicotine is responsible for the chemicaladdiction. Tobacco users find it too difficult to quit because both thenicotine cravings and ritual behaviors are too severe and ingrained. Theprior art has therefore developed a multitude of therapies, devices, andmethods for helping people quit tobacco. Many of them follow similarritual patterns of putting things in the mouth.

[0006] Given the large number of users who continue using tobacco, itcan be assumed that no prior art attempt has been completely successful.

[0007] Many smokers have decided to continue smoking, no matter what.But recent changes in social behavior and even the Law have put manyplaces out-of-bounds for smokers, e.g., commercial airflights,restaurants, school, work, home, etc. So in these situations, suchsmokers need a temporary relief from the pains of abstinence. Otherswanting to quit altogether also need effective relief from cravings.

[0008] One line of therapy for tobacco-addiction is aversion therapy. Anattempt is preferably made to associate some ill-effect whenever theuser engages in the addiction. For example, ANTABUSE is a brand oftetraethylthiuram disulfide that will induce nausea, vomiting, andheadache if the user drinks alcohol. A chemical reaction in thebloodstream generates acetaldehyde, and it's this compound that producesthe aversive symptoms. A similar, less severe aversion therapy is knownas TEMPOSIL, e.g., citrated calcium carbamide.

[0009] Conventional behavioral aversion therapies also include hypnosisand electroshock. In hypnosis, a suggestion is preferably made to quittobacco outright, or associate it with a bad taste or smell. Inelectroshock therapy, a harmless shock is sent, for example, to punishthe user each time a cigarette is smoked. An interesting observation ispreferably made by W. L. Jenkins, combinations of warm heat and shockare interpreted as hot. (Journal of Experimental Psychology, 1938,v22:564-572.) So a more effective, but harmless electroshock therapywould include the application of warm heat, perhaps even constant warmheat punctuated by the shocks.

[0010] Theodore Stanley, et al., observed in U.S. Pat. No. 5,824,334,issued Oct. 20, 1998, that heavy smokers seem to adjust their levels ofnicotine in their blood to stay within narrow limits. They also statethat “a smoker's craving for tobacco is not mitigated by a relativelylow, constant level of nicotine.” When nicotine is received throughsmoking, the rapid absorption of the nicotine through the lungs resultsin an initial peak of nicotine which then trails off. The blood-levelconcentration peak produced by cigarettes is higher and sharper thansteadier levels obtained from patches or gums. Such initial peak is saidto be 30-40 nanograms per milliliter of blood, and is reached within tenminutes. So Stanley, et al., concluded that quick-rise effects areprobably necessary for more complete relief from craving in the earlystages of withdrawal.

[0011] One of the present inventors, Paul Wilhelmsen, was issued U.S.Pat. No. 6,248,760, on Jun. 19, 2001. It describes a tablet giving rapidrelease of nicotine for transmucousal administration. He says quick-riseeffects are necessary for relief from craving. A nicotine layer in anoral tablet is designed to be rapidly absorbed through the tissuesinside the user's mouth.

SUMMARY OF THE INVENTION

[0012] Briefly, a method and oral tablet embodiment of the presentinvention comprise a flash dissolve nicotine payload disposed in adelivery carrier that is then placed in the mouth of a user. Forexample, a pill, tablet, or capsule is a suitable oral delivery form.The nicotine payload liberates from its fixing with the delivery carrierall at once sometime after being wetted inside the mouth. The result isa short, intense nicotine dose pulse that enters the bloodstream andcirculates to the brain before being filtered out by the liver. Suchrapid spiking of nicotine mimics that received from a single puff of acigarette. Multiple bursts are received by multiple takings.

[0013] In alternative embodiments of the present invention, a pluralityof flash dissolve nicotine payloads are carried in time-releaseenvelopes that burst sequentially over time. The number of bursts andinterval time between them are similar to those obtained from theordinary smoking of one whole cigarette.

[0014] An advantage of the present invention is a method and oral tabletare provided for relief of cravings in a tobacco-addicted user.

[0015] Another advantage of the present invention is that a method andoral tablet are provided for more satisfying delivery of nicotine to thebrain of an addicted user.

[0016] A still further advantage of the present invention is that amethod and oral tablet are provided for cigarette smokers wishing toquit.

[0017] Another advantage of the present invention is that a method andoral tablet are provided for cigarette smokers wishing to bridge overperiods when they cannot smoke a cigarette.

[0018] An advantage of the present invention is a method and oral tabletare provided for pulsing nicotine into the bloodflow to the brain of auser.

[0019] The above and still further objects, features, and advantages ofthe present invention will become apparent upon consideration of thefollowing detailed description of specific embodiments thereof,especially when taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020]FIG. 1 is a flowchart of a means for abstaining from tobacco-useembodiment of the present invention;

[0021]FIG. 2 is a cross sectional diagram of a pill embodiment of thepresent invention;

[0022]FIG. 3 is a flowchart of a quit-smoking embodiment of the presentinvention; and

[0023]FIG. 4 is a perspective view of a layered oral tablet embodimentof the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0024]FIG. 1 represents a means for abstaining from tobacco use, and isreferred to herein by the general reference numeral 100. Such comprisesa means 102 for fixing a compound of nicotine to an oral deliverycarrier, e.g. to enable easy counting, measurement, and placement in auser's mouth. A means 104 for disposing a part of such fixed nicotine isincluded, and it is important that such provides for a flash-dissolutionin saliva of all such part. Since a tablet or pill is a usual form ofcarrier, a single coating or layer with high surface area relative toerosion depth is needed. The whole surface area is preferably exposed tothe user's saliva all-at-once, whether a surface layer or buried layerin the pill.

[0025] A pill 106 produced at this stage of manufacturing is a usefulcommercial product to control nicotine cravings.

[0026] A means 108 is for disposing a compliance or persuading agent inthe pill 106. Two kinds of compliance agents are preferred. One to makeany usage tolerable, e.g., candy coating or flavors to mask the bittertaste of the nicotine compound. The other kind deters too much usage,e.g., abuse.

[0027] This second deterrent kind may depend on individual dosescarrying small amounts of agent that accumulate to a threshold levelwhen too many doses have been taken in a predetermined time. Anotherdeterrent mechanism can depend on the parts “A” and “B” to produce anasty part “C”. ANTABUSE reacts this way with alcohol to make usersviolently ill. Many other component combinations like this exist inconventional commercial products.

[0028]FIG. 2 illustrates a pill embodiment of the present invention, andis referred to by the general reference numeral 200. The pill 200implements means 102 and 104 (FIG. 1), but does so twice. One inside theother. A coating 202 provides a compliance agent, but is otherwiseinert. A bubble layer 204 comprises a compound of nicotine that is flashreleased in saliva when outer layer 202 is eroded. A more inner layer206 provides a time delay to any flash release of a last nicotinepayload 208. The time delay mimics that between puffs of a cigarette, orbetween whole cigarettes by a smoker. So the time delay can be a minuteto ten minutes.

[0029]FIG. 3 represents a quit-smoking embodiment of the presentinvention, and is referred to by the general reference numeral 300. Suchuses a means 302 to rapidly place nicotine into solution in the salivaof a user's mouth. A means 304 provides a mechanism for waiting betweennicotine bursts. Such delay can be on the order of one to ten minutes.The mechanism can be as simple as burying layers inside layers, as inFIG. 2. Another mechanism includes taking separate pills at differenttimes. A means 306 delivers a subsequent spike of nicotine through themouth membranes of a user. A means 308 provides nicotine delivered inmultiple bursts to the brain in the bloodflow of a user. The result is asmoker is relieved enough from addiction cravings to give up smoking,altogether or only temporarily.

[0030]FIG. 4 represents a transmucousal tablet embodiment of the presentinvention, and is referred to herein by the general reference numeral400. The transmucousal tablet 400 provides a short pulse of nicotineinto the bloodstream through the membranes of the mouth of a user. Athin nicotine layer 402 is disposed on a core 404, and is intended toflash dissolve in the mouth and be absorbed into the user's bloodflow tothe brain via the heart and lungs. No nicotine is present in the core404, it simply acts as a carrier of the nicotine. In other embodimentsof the present invention, the core 404 further provides minerals,vitamins, good taste, and/or abuse-deterrents.

[0031] There are a number of method embodiments of the present inventionfor fabricating the thin nicotine layer 402 in the transmucousal tablet400, and also FIGS. 1-3. For example, a syrup is prepared by mixing0.2004 gram of sucrose, 0.2017 gram of nicotine, and 0.2034 gram ofwater. A thin layer of this syrup is spread with a paintbrush on top ofa conventional antacid tablet, and allowed to dry. A wet layer typicallypreferably weighs 5.5 milligrams. In a test that was conducted, thetablet was 1.7 cm in diameter and 0.4 cm thick. The total weight of thetablet was 1.5767 grams. When such tablet is placed in the mouth, thenicotine layer dissolves and gives a short, intense pulse of about 1.8milligrams of nicotine.

[0032] In a second method, a mixture is preferably made from 4.0289grams of powdered calcium carbonate, 1.0683 grams of powdered magnesiumhydroxide, 1.0856 grams of caffeine, and 40.4747 gram of powderedsucrose. One gram of the above mixture is placed in the cavity of adevice used to prepare tablets. The material is compressed to form acompact tablet. A second mixture is preferably made of 0.6124 gram ofnicotine tartrate and 8.0234 grams of sucrose. A conventionaltablet-making device is opened, and 0.0823 gram of the second mixture issprinkled on top of the previously manufactured tablet. The plunger ofthe conventional tablet-making device is reinserted and pressure appliedto fuse the second mixture onto the previously manufactured tablet. Theresulting compound tablet is removed. A nicotine layer is above andadherent to a non-nicotine layer. When this tablet is placed in themouth, the nicotine layer dissolves to provide a short pulse of aboutone milligram of the nicotine base. The calcium carbonate and magnesiumhydroxide have a basic reaction that promotes the absorption of thenicotine from nicotine tartrate. The addition of magnesium hydroxide tothe calcium will reduce the tendency of the calcium to causeconstipation.

[0033] A third method places one gram of the first mixture in the secondmethod and places it in the cavity of a device for making tablets. Thematerial is then compressed to a compact non-nicotine layer. Thetablet-making device is opened, and 0.0631 gram of the second mixture ofthe second method is sprinkled on the top of the non-nicotine layer. Theplunger is reinserted in the tablet-making device, and pressure is usedto fuse the second mixture onto the non-nicotine layer thereby formingan overlying layer including nicotine.

[0034] The plunger is removed and 0.1256 gram of the first mixture fromthe second method is sprinkled on the top of the composite tablet. Theplunger is reinserted into the cavity of the tablet-making device andpressure is used to fuse the new material on top of the tablet, therebyforming a overlying layer which does not include nicotine.

[0035] The plunger is removed and 0.0687 gram of the second mixture fromthe second method is sprinkled on top of the tablet. The plunger isagain reinserted into the cavity of the tablet-making device andpressure is applied to form an overlying, nicotine layer and to fuse allof the layers together.

[0036] The resulting tablet thus has a first non-nicotine layer, a firstnicotine layer, a second non-nicotine layer, and a second nicotinelayer.

[0037] When placed in the mouth, the layers dissolves sequentially toprovide two sharp pulses of nicotine separated by about one and a halfminutes.

[0038] In a fourth method embodiment for making tablets, an exemplarysyrup is prepared by mixing, e.g., 4.0412 grams of sucrose, 1.2018 gramsof nicotine tartrate, and 10.6523 grams of water. An antacid tablet isdipped into the syrup and then allowed to dry. The original weight ofthe antacid tablet is 1.5465 grams. The tablet after dipping and dryingpreferably weighs 1.5678 grams. When this tablet is placed in the mouth,the layer including nicotine dissolves and gives a short, intense pulseof about 1.5 milligrams of nicotine.

[0039] A fifth method begins with a thick paste mixed, e.g., from 0.2134gm of potato starch, 0.2246 gm of nicotine and 0.2107 gm of water. Abrewer's yeast tablet is painted on one side with a confectioner'sglaze, e.g., as marketed by Mantrose-Haeuser Company. Such glazeprevents nicotine paste from penetrating the brewer's yeast tablet.After the glaze has dried, the glazed brewer's yeast tablet preferablyweighs 0.7478 gm. A thin layer of the aforementioned paste is painted onthe glazed surface. The wet paste layer preferably weighs 5.2milligrams, of which the nicotine is calculated to be 1.7 mg. The pasteis allowed to dry. When this tablet is placed in the mouth, the layerincluding nicotine dissolves in a few seconds into the saliva of themouth, and gives a short, intense nicotine pulse. Thereafter thebrewer's yeast tablet along with the confectioner's glaze is swallowed.

[0040] In a sixth exemplary method embodiment of the present invention,a syrup is prepared by mixing 0.2104 gm of honey, 0.2137 gm nicotine and0.2209 gm of water. Disks are punched from polyethylene sheeting. Thedisks are 12 mm in diameter and 0.67 mm in thickness. One of these diskspreferably weighs 0.0736 gm. A thin layer of the aforementioned syrup ispainted on top of the polyethylene disk. The wet layer preferably weighs4.7 milligrams, of which 1.5 milligrams is nicotine. The syrup isallowed to dry. The resulting film is lightly dusted with amorphouscolloidal silicon dioxide to reduce stickingness. When this tablet isplaced in the mouth, the layer including nicotine dissolves in a fewseconds and gives a short, intense nicotine pulse. Thereafter, thepolyethylene disk is spat out.

[0041] In a seventh exemplary method embodiment of the presentinvention, a number of disks are punched from Whatman #1 qualitativefilter paper. The disks are 12 mm in diameter and one of them typicallypreferably weighs 10.1 milligrams. A solution is preferably made byadding 0.2245 gm of nicotine to 0.5326 gm of water. A one-milliliterhypodermic syringe is partially filled with the nicotine solution. Asmall pendant drop, weighing 4.8 mg, is preferably made to appear on thetip of the hypodermic needle. Such small drop is then transferred to thefilter disk. The nicotine solution is absorbed on the inert-to-nicotinecellulose fibers of the filter paper. The filter paper with its absorbedsolution preferably weighs 14.9 milligrams, and is allowed to dry. Theresult is paper fibers coated with typically 1.4 mg of nicotine andempty space between the coated fibers. Such disk absorbs saliva whenplaced in the mouth. This dissolves the nicotine, and is absorbed by thetissues of the oral mucousal and/or the tongue. The result is a sharp,intense nicotine pulse. The small disk of filter paper may then beswallowed.

[0042] In an eighth exemplary method embodiment of the presentinvention, a number of disks are punched from DISOLVO, a trademarkedwater-soluble paper from D. Robbins & Company. The disks are 12 mm indiameter and 0.06 mm in thickness. One of these disks preferably weighs7.2 milligrams. The disk is placed on a waterproof surface, e.g., apolypropylene specimen cup bottom. A solution is preferably made byadding 0.1552 gm of nicotine tartrate to 0.3259 gm of water. Ahypodermic syringe is then used to place 14.1 milligrams of the nicotinetartrate solution on a DISOLVO disk. The somewhat swollen disk includingthe solution is allowed to dry on a waterproof surface. After drying,the paper regains its original appearance and is mechanicallyself-supporting. Such paper disk rapidly disintegrates in the saliva ofthe mouth and gives a nicotine pulse.

[0043] In a ninth exemplary method embodiment of the present invention,disks are punched from sheets of DISOLVO. The disks are 12 mm indiameter and 0.06 mm in thickness. One of these disks preferably weighs7.2 milligrams. The disk is placed on a waterproof surface like in theeighth method. A small amount of nicotine base is drawn into aone-milliliter hypodermic syringe. A small pendant drop is preferablymade to appear on the tip of the hypodermic syringe needle. Small dropssuch as these, were experimentally found to include a calculated 1.2milligrams of nicotine base. This is then transferred to the disk, whichabsorbed it. The disk with the added nicotine preferably weighs 8.4milligrams. Such paper disk, when placed in the mouth, rapidlydisintegrates in the saliva of the mouth and gives a sharp, intensenicotine burst.

[0044] In a tenth exemplary method embodiment of the present invention,a solution of nicotine citrate is preferably made by adding 0.1847 gm ofnicotine base, 0.2047 gm of citric acid and 0.5267 gm of water. Ahypodermic syringe is then used to place 9.5 milligrams of thissolution, of which 1.8 mg is nicotine base, on a DISOLVO disk. The diskwith the nicotine citrate is allowed to dry on the waterproof surface.Such disk when placed in the mouth, rapidly disintegrates in the salivaand gives a nicotine pulse, less sharp and intense than the base.

[0045] In an eleventh exemplary method embodiment of the presentinvention, an ALTOID cinnamon flavored mint is painted on one side witha confectioner's glaze made by Mantrose-Haeuser Company. The glazeprevents the nicotine from penetrating the confection. The glaze isallowed to dry and the mint with the dried glaze preferably weighs0.6977 gm. A solution is preferably made by mixing and heating 0.2678 gmof KNOX unflavored gelatin and 0.5893 gm of water. The gelatin solutionis allowed to cool and0.2145 gm of nicotine base is added and disperseduniformly throughout the gelatin solution. A thin layer of thenicotine-gelatin solution is spread on the dried glaze. The coatedtablet preferably weighs 0.7065 gm. From the difference in tabletweights and the nicotine concentration in the coating the nicotinecontent is calculated to be about 1.7 mg. The gelatin layer gels in afew minutes. When this tablet is placed in the mouth, the layerincluding nicotine dissolves in the saliva in a few seconds, and gives asharp intense nicotine pulse. Thereafter the mint is allowed to dissolvein the mouth and is swallowed.

[0046] In a twelfth exemplary method embodiment of the presentinvention, a solution of citric acid is prepared by dissolving 0.1687 gmof citric acid in 0.3323 gm of water. Then 0.0121 gm of nicotinecitrate, of nineteen percent nicotine base, is applied to a DISOLVO diskon a waterproof surface. The disk with the nicotine citrate solution of2.3 mg nicotine is allowed to dry. Then, 0.0317 gm of citric acidsolution, 0.01 g citric acid, is added and allowed to dry. Such diskwhen placed in the mouth rapidly disintegrates and gives a more moderatepulse of nicotine.

[0047] In a thirteenth exemplary method embodiment of the presentinvention, a solution is preferably made by adding 0.1728 gm of water to0.2305 gm of a nicotine sulfate solution which includes forty percentnicotine base. The resulting solution includes 22.9 percent nicotinebase. About 7.4 mg of this solution, 1.6 mg nicotine, is absorbed in a12 mm disk of Watman #1 filter paper. The disk is then dried. A fewmilligrams of sodium bicarbonate is sprinkled on the nicotine includingdisk. The sodium bicarbonate is pressed into the pores of the filterpaper by placing it between two sheets of 4 mil polyethylene andpressing it with a small spatula. About 3.6 milligrams of sodiumbicarbonate will be imbedded in the filter paper. The resulting diskwhen placed in the mouth gives a very rapid nicotine pulse, comparableto nicotine base administrations. In another variation of this example,the paper surface is roughened by lightly abrading it with needle-pointtweezers. A quantity of sodium bicarbonate is placed on the surface.When smoothed out with a spatula, the fibers bind the bicarbonatepowder, giving a paper surface less prone to shed bicarbonate particles.Such provides an intimate mechanical composite ofnicotine-salt-impregnated or coated paper fibers surrounding powderedsodium bicarbonate.

[0048] In a fourteenth exemplary method embodiment of the presentinvention, an irregularly-shaped piece of Watman #1 paper weighing 11.9mg is fabricated. About 14.3 mg of a nicotine tartrate solutionincluding 11.5 percent nicotine is injected into the paper, and allowedto dry. The performance of this paper when placed in the mouth isindistinguishable from similar ones on circular disks.

[0049] In a fifteenth exemplary method embodiment of the presentinvention, disks of nicotine including DISOLVO paper are made, eachlayer including 0.5 to 5 milligrams of nicotine. Bicarbonate may beadded to amplify the effective nicotine pulse. Dissolution of thenicotine layer is less than one minute, preferably less than thirtyseconds. The preferred layer is a coating which does not immediatelydissolve, e.g., confectioner's glaze. The dissolution time of thenicotine-including layer is at least as long as the dissolution time ofother layer. Layer is a slow-dissolving non-toxic layer of material. Acast sugar film such as LIFE-SAVERS™, the popular candy, is appropriate,as would a gelatin film. Dissolution in saliva in the mouth is extendedto more than the nicotine including layers, e.g., in the range of one totwenty minutes. Recognizable separate pulses of nicotine are released tothe user. The spacing between nicotine bursts is a function of thedesired effect on the senses of the user. Since a single nicotine pulsehas an onset time of about thirty seconds, this sets the minimum spacingbetween pulses.

[0050] In an alternative multi-layered embodiment, one layer is aslow-dissolving layer, such as a cast sugar film. It dissolves in one totwenty minutes, more preferably one to five minutes, and a sharp pulseof nicotine is experienced. A second layer then dissolves in one to fiveminutes to expose another nicotine layer. Such delivers a second sharpnicotine pulse in less than one minute.

[0051] A nicotine-including layer may be disposed separately on bothsides of a flat, slow-dissolving layer. Alternatively, such maycompletely surround the layer. The slow-dissolving layer preferablycompletely surrounds nicotine layer to ensure a time delay between thenicotine pulses experienced by the user.

[0052] Embodiments of the present invention can be made with graduatedconcentrations of nicotine. Smokers take decreasing doses over days orweeks to break free of their addiction to nicotine and smoking. Such cansupply the usual dose of nicotine normally obtained from smoking, whileavoiding exposure to the toxic and carcinogenic combustion products.

[0053] Many alternative ways are available to engineer rapidlydissolving nicotine layers, e.g., the geometry of the tablet, thethickness of the layers, and the materials employed. In a preferredembodiment of this invention, the layer that includes nicotine ornicotine-including compounds will dissolve in less than two minutes. Thematerials other than nicotine or nicotine including compounds caninclude sugars, non-nutritive sweeteners, coloring agents, flavoringagents, effervescent agents, binders, and other compatible materials.

[0054] It is therefore an object of the instant invention to provide anaversive experience when too many tablets are taken in too short a time.A multiplicity of aversive sensations is preferable, wherein eachaversive sensation by itself is tolerable.

[0055] The combination of sensations aversive at a sufficient level orin sufficient combination, may be incorporated within a single tablet.One may also incorporate different embodiments of the instant invention,such that there is a high probability that the use of a multiplicity ofthe instant tablet will result in an even more aversive sensationexperience due to the more aversive combination of aversive sensations,whether taste or other sensations.

[0056] Many chemicals induce sensations which may not be one of the fiverecognized taste sensations and yet may be a sensation received by thetongue, skin or mucous membranes.

[0057] The part of the tablet not including nicotine can be anythingthat is acceptable to take by mouth. It can be inert as, for example,filter paper or plastic. It can be in any shape in any size, of anydimension or dimensionality, subject only to being able to be takenorally. It can include caffeine, vitamins, flavoring materials,buffering agents, sugars, non-nutritive sweeteners, materials givingbitter, hot, painful or other tastes or sensations tolerable at somelevel but intolerable at a higher level, and other compatible materials.

[0058] Although particular embodiments of the present invention havebeen described and illustrated, such is not intended to limit theinvention. Modifications and changes will no doubt become apparent tothose skilled in the art, and it is intended that the invention only belimited by the scope of the appended claims.

The invention claimed is
 1. A method for assuaging tobacco addition,comprising the steps of: introducing nicotine into a user's bloodstreamat a place where the bloodflow will carry said nicotine doses to thebrain before passing through the liver; and pulsing individual doses ofnicotine into said user's bloodstream to generate a sharp spike ofnicotine level in the blood that mimics that received from individualpuffs of smoking tobacco.
 2. The method of claim 1, wherein the step ofintroducing depends on oral placing of a delivery carrier that conveyssaid nicotine as a payload to said bloodstream.
 3. The method of claim1, further comprising the step of: instantly dissolving away anydelivery carrier that conveys said nicotine as a payload.
 4. The methodof claim 1, further comprising the step of: including an abuse-deterrentadditive in any delivery carrier that conveys said nicotine as a payloadto said bloodstream.
 5. The method of claim 1, further comprising thestep of: including an abuse-deterrent additive in a delivery carrierthat conveys said nicotine as a payload to said bloodstream; wherein,said additive depends on an accumulation over a plurality of doses toreach a particular threshold level before generating an aversive effecton said user.
 6. The method of claim 1, further comprising the step of:including a different one of a plurality of synergistic additives in acorresponding plurality of delivery vehicles that one-at-time carry saidnicotine as a payload to said bloodstream; wherein, particularcombinations of said plurality of synergistic additives generate anabuse-deterrent with an aversive effect on said user.
 7. An oral tablet,comprising: a payload means for fixing a compound of nicotine; a carriermeans for delivering the payload means to the mouth of atobacco-addicted user; a release means for dispersing said compound ofnicotine when immersed in saliva; and a pulse means for a sudden releaseof said compound of nicotine; wherein, a burst of nicotine is providedfor absorption into the bloodstream of a user to circulate to the brainbefore passing through the liver.
 8. The oral tablet of claim 7, furthercomprising: repeating pulse means for providing more than one suddenrelease of said compound of nicotine; and quiescent means for separatingeach sudden release from a next.
 9. The oral tablet of claim 7, furthercomprising: disintegrating means for eroding the carrier means to exposethe payload means.
 10. A method for assuaging nicotine cravings intobacco-addicted users, the method comprising the steps of: first,placing a compound of nicotine into the mouth of a user to go intosolution in the saliva and then be absorbed into the bloodstream throughmucous membranes; second, waiting a minimum period to allow saidnicotine in said bloodstream to spike and fall off; third, placinganother compound of nicotine into the mouth of said user to also go intosolution in said saliva and also be absorbed into the bloodstreamthrough said mucous membranes; and fourth, allowing another saidnicotine to spike in concentration level in said bloodstream and falloff again; wherein, said spikings and a quiescent period betweensimulate nicotine-concentration level fluctuations that occur duringordinary smoking of a cigarette by said user.
 11. The method of claim 10wherein the steps of placing include use of at least one of: an oraltablet; an under-the-tongue spray; a flash-dissolve paper; and aninhaler.
 12. The method of claim 10, wherein: the step of waitingincludes dissolving through an inert layer in a tablet that eventuallyexposes one of said compounds of nicotine after a predetermined delaywhile in the mouth of a user.